Investigating how KIR2DL2 affects T-cell function in cancer treatment
Official title: KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10813170 · Data updated 2026-11-12
This study is looking at how a specific receptor on T-cells, called KIR2DL2, affects their ability to fight pancreatic cancer, with the goal of finding better ways to improve immunotherapy treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $224,506 |
| NIH project number | 5R21CA280233-02 |
| Project ID | NIH-10813170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with pancreatic cancer who are undergoing or considering adoptive cell therapy.
✕Less likely to help
Patients with cancers other than pancreatic cancer or those not eligible for immunotherapy may not benefit from this research.
What this research studies
This research explores the role of KIR2DL2, a receptor found on certain T-cells, in regulating their ability to fight cancer. It examines how KIR2DL2 expression influences T-cell activation and survival, particularly in the context of adoptive cell therapies for pancreatic cancer. By studying the effects of KIR2DL2 on T-cell behavior, the research aims to identify ways to enhance the effectiveness of immunotherapy treatments for patients. The approach includes both laboratory experiments and analysis of patient samples to understand the implications of KIR2DL2 in cancer progression.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies that enhance T-cell responses against tumors, potentially increasing survival rates for cancer patients.
How similar studies have gone: Previous research has shown that targeting immune checkpoints can enhance T-cell responses in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Abate-Daga, Daniel — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Abate-Daga, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Central Laboratory Core for Advanced Cancer Research
A central laboratory core provides shared, specialized services to cancer researchers to help advance patient-focused studies.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Administration & Coordinating Core
This grant funds a central hub to help coordinate cancer research efforts at a major cancer center so researchers can work together more efficiently.
-
Developmental and Career Enhancement Core (for researchers)
A dedicated program to help researchers build skills and advance their careers over several years.
-
Central Laboratory Core for Cancer Research
A cancer research center is funding a shared lab core to support various studies over the next five years.
-
Exploring how HPV-related cancers affect people living with HIV and what helps survival
A patient-friendly look at a project studying how HPV-related cancers and HIV interact and what factors influence survival.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.